Too Much of a Rush for Clinical Trials With iPS Cells
By AJW,
The Asahi Shimbun
| 06. 28. 2013
The world’s first clinical application of induced pluripotent stem (iPS) cell technologies for regenerative medicine for humans has just got the go-ahead in Japan.
People suffering from intractable diseases that cannot be effectively treated with conventional medicine are pinning their hopes on the development of new treatment methods of regenerative medicine.
What we find worrisome is the somewhat over-eager attitude of the Abe administration, which wants to make iPS technology one of the pillars of its economic growth strategy. But the safety of the technology, much less its effectiveness, has yet to be confirmed.
The government must not push researchers for results. Nor should it lose interest if they suffer minor setbacks. For that matter, it must not give undue favor and spoil a “big-name rookie.” If the government engages in such behavior, it would likely do no good and much harm.
iPS cell technology was developed by Shinya Yamanaka, a Kyoto University professor who won a Nobel Prize in Physiology or Medicine for his research. iPS cells are engineered by introducing specific genes into cells derived from the skin...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Alcott Wei, South China Morning Post | 07.13.2024
China has banned all clinical research involving germline genome editing under a newly released ethics guideline.
Germline gene engineering relates to altering the DNA in sperm, eggs or early embryos to introduce changes that can be inherited.
“Any clinical research...
By Staff, Japan Times | 07.10.2024
Photo by Roméo A. on Unsplash
How did Japanese society, which was supposed to have transformed into a democracy after World War II, justify discrimination against people with disabilities and openly endorse eugenics?
This is a key question people may...